AlphAIAlphAI — Financial news for AI agents
tradingview.com$HUM

Earnings to watch: Humana (HUM) reports Q3 results tomorrow

Humana (HUM) is set to report Q3 results, with analysts expecting 25.2% revenue growth. Last quarter, it beat revenue and EPS estimates, reporting $40.87B in revenue and adding 200,800 customers. Peers Elevance Health and CVS Health also beat expectations. Humana's stock is up 4.1% over the last month, with an average price target of $465.13.

Original reporting
tradingview.com
Published Nov 5, 2026, 3:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Earnings to watch: Humana (HUM) reports Q3 results tomorrow — source image
Source · tradingview.com
Decision brief

The 30-second read

$HUMNeutralLow
01

Why it matters

The earnings release will confirm whether growth trends continue, influencing short‑term price action.

02

Market read

Earnings preview for a large insurer; traders will monitor the actual results for directional cues.

03

What to watch

Potential impact of Medicare policy changes or enrollment trends not discussed.

Relevance 4/10Novelty 2/10Timing: pre‑market tomorrow

Background

Humana has recently beat revenue and EPS expectations and added members, positioning it as a strong performer in the health insurance space.

Company-level read

Ticker impact

$HUMNeutralMedium confidence
Context

Humana is scheduled to report Q3 results tomorrow; the article previews expectations and past performance.

Expected impact

potential swing as market prices in the earnings surprise.

Evidence & confidence

No new guidance is disclosed; traders will react to the actual numbers when released.

Market effects

Sector

Health insurance sector may see modest movement based on Humana's earnings outcome.

Regional

U.S. market participants tracking insurer earnings will watch the release.

Global

Limited to U.S. insurers; no broader macro impact.

Counterpoint

What could challenge this read

If Humana misses expectations, the stock could underperform peers despite recent price gains.

Key entities

  • company
    Humana

    U.S. health insurance provider.

Read at source← All news

Related articles

$HUMMedAI 8/10

Humana Inc (HUM) (Q3 2026) Earnings Call Highlights: Raised EPS Outlook, Star Ratings

Humana Inc (HUM) raised its 2027 EPS outlook, citing cost savings, improved product positioning, and lower onboarding costs. The company expects higher core trends and Part D trends but faces Stars rating challenges. It plans to invest in growth and return capital to shareholders, with more details expected in December. Management also discussed cost pressures in its CenterWell PCO business and competitive dynamics in Medicare Advantage.

finance.yahoo.com
$HUMHighAI 8/10

Humana 3Q 2026: Revenue $41.16B, EPS $1.33 — 10-Q Summary

Humana reported 3Q 2026 revenue of $41.16B, up 26.1% YoY, driven by Medicare membership growth and higher premiums. Net income fell 16.9% to $162M, with EPS at $1.33. Insurance membership grew 20.3%, but the segment saw a $303M operating loss. CenterWell revenue rose 40.4% to $1.9B, though costs increased.

tradingview.com
$HUMMedAI 8/10

Humana Inc. Q3 2026 Earnings Call Summary

Humana Inc. raised its 2026 adjusted EPS outlook due to strong operational performance and medical cost trends. The company is focusing on top quartile Star ratings and expects 2027 membership growth. A joint venture with BlackRock aims to improve balance sheet efficiency. Humana anticipates a 3%+ individual MA margin by 2028, with 2027 showing progress. The divestment of Gentiva is expected to close in Q4 2026, providing $900 million in pretax proceeds.

finance.yahoo.com
$HUMHighAI 8/10

Humana (HUM) Q3 2026 Earnings Call Transcript

Humana (HUM) reported Q3 2026 earnings with adjusted EPS of $17.17 YTD and a Q3 loss of $0.70, down from $3.24 YoY. Full-year adjusted EPS guidance raised to at least $9.50. GAAP EPS for Q3 was $1.33, down from $1.62 in 2025. The company expects $900M in pretax proceeds from Gentiva divestment. Medicare Advantage enrollment and Star ratings improved, but Part D cost trends are expected to rise to 14-15% in 2027.

fool.com
$HUMMedAI 8/10

Humana Raises 2026 Profit Forecast

Humana reported better-than-expected quarterly results and raised its 2026 adjusted EPS forecast to at least $9.50 from $9. Medical and pharmacy costs rose less than expected. The company expects 3% pretax margins in Medicare Advantage by 2028. Shares fell 1.4% premarket. Year-to-date, the stock is up 61%.

briefs.co